Atrial fibrillation, or Afib, kills about 130,000 people worldwide every year. It also affects 3 to 6 million people in the United States alone and is a leading factor in prolonged hospital stays, according to the Centers for Disease Control and Prevention.

Ashutosh Banerjee, general manager of GE Healthcare Diagnostic Cardiology

Merit Medical Systems Inc. announced the U.S. commercial launch of the PreludeSync Evo radial compression device. The PreludeSync Evo is a sterile, single-use, disposable device used to assist in gaining hemostasis of the arterial percutaneous access site following catheterization procedures.

FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices

The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-coated devices used to treat peripheral artery disease (PAD) following its review of long-term follow-up clinical data. The agency said five-year results from three randomized trials showed an increased mortality rate in patients treated with these devices compared to those treated with uncoated devices. While these data provide reason for caution, the FDA noted that the devices still provide documented short-term benefits, and healthcare providers should consider all options for their PAD patients.

AtriCure Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for AtriClip left atrial appendage (LAA) management devices. These include changing the indication from occlusion of the LAA to exclusion, and also adding electrical isolation as a labeling claim.

A new 3-D magnetic resonance imaging (MRI) computing technique developed by scientists in WMG at the University of Warwick focuses on hierarchical template matching (HTM) to diagnose cardiac disease without the use of gadolinium contrast. The technique is explored in an article in the journal Scientific Reports.

Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy heart muscle tissue.

Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of heartbeat abnormalities. The facility, which includes a brand new procedural laboratory, will offer patients a state-of-the-art program delivering cutting-edge electrophysiology procedures, including complex ablations, minimally-invasive pacemaker and defibrillator implantations, and structural interventions. The space also includes a newly renovated reception area and a comfortable, tranquil waiting room for patients’ families and friends.

Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for below-the-knee (BTK) use of its MagicTouch drug-coated balloon catheter (DCB) for the treatment of peripheral artery disease (PAD). The company is now in a position to potentially disrupt this market and become a threat to larger manufacturers that have an established presence in the peripheral space, according to data and analytics company GlobalData.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now